Cogent Biosciences Reports Recent Business Highlights and First Quarter 2026 Financial Results
Cogent Biosciences ended the first quarter of 2026 with $866.4 million in cash, which the company states is sufficient to fund operations into 2028 and support the commercialization of bezuclastinib. The company announced that the FDA accepted its NDA for bezuclastinib in Non-Advanced Systemic Mastocytosis with a PDUFA target action date of December 30, 2026, and submitted a second NDA for GIST under the Real-Time Oncology Review program.
Key figures
- Guidance
- sufficient to fund operations into 2028
- Net loss
- $97.4 million
- Pdufa date
- December 30, 2026
- Ga expenses
- $28.2 million
- Rd expenses
- $75.4 million
- Atm proceeds
- $45.7 million
- Cash position
- $866.4 million
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.